MolecularMD: MolecularMD and Mayo Clinic Enter Into Sub-License Agreement for the Detection of Drug Resistant Mutations in Leukemia Patients

Posted by rob on April 20, 2009 under Uncategorized | Comments are off for this article

PORTLAND, OR (MARKET WIRE) MolecularMD Corp, a developer and provider of cancer-based pharmacogenomic diagnostic tests, announced today that it has granted a sub-license agreement for the detection of ABL kinase mutations in Chronic Myelogenous Leukemia (CML) patients to Mayo Foundation for Medical Education and Research (Mayo Clinic). (Source: Market Wire – Pharmaceuticals and Biotech)